SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza

This article was originally published here

SAB-176 is a novel anti-influenza human immunoglobulin G (IgG) immunotherapy designed to address the limitations of current treatment for severe seasonal influenza. This fully human polyclonal antibody therapeutic

The post SAB Biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply